Luminus Biosciences

LBI-0942

THERAPEUTIC AREA

SOLID TUMOR CANCER

Indications

Breast, Lung, Pancreas Cancer


REGULATORY PATHWAY

Generic ANDA

TARGET INDICATION

Contract development funds company and builds out commercial manufacturing process for Luminus Nano medicines

CURRENT DEVELOPMENT STATUS

Active CMC development in process


NEXT DEVELOPMENT PHASE

Clinical studies

TIME TO HUMAN BENEFIT

Bioequivalence study to begin in the 1st quarter of 2020


IMMEDIATE FUNDING REQUIRED?

No, fully funded by partner